jte-907 has been researched along with Inflammatory-Bowel-Diseases* in 1 studies
1 other study(ies) available for jte-907 and Inflammatory-Bowel-Diseases
| Article | Year |
|---|---|
Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease.
Cannabinoids are known to possess anti-inflammatory and immunomodulatory properties, but the mechanisms involved are not fully understood. CB2 is the cannabinoid receptor that is expressed primarily on hematopoietic cells and mediates the immunoregulatory functions of cannabinoids. In order to study the effect of JTE907, a selective/inverse agonist of CB2 with anti-inflammatory properties, on the differentiation of T cell subtypes, we used an in vitro system of Th lineage-specific differentiation of naïve CD4 Topics: Animals; Anti-Inflammatory Agents; Cell Differentiation; Colitis; Colon; Cytokines; Dioxoles; Disease Models, Animal; Inflammation; Inflammatory Bowel Diseases; Male; Mice, Inbred C57BL; Phenotype; Quinolones; Receptor, Cannabinoid, CB2; Spleen; T-Lymphocytes | 2019 |